News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,315 Results
Type
Article (43695)
Company Profile (473)
Press Release (694135)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209321)
Career Advice (2039)
Deals (36152)
Drug Delivery (119)
Drug Development (83974)
Employer Resources (174)
FDA (16691)
Job Trends (15188)
News (354164)
Policy (33278)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2657)
Accelerated approval (35)
Adcomms (28)
Allergies (146)
Alliances (51112)
ALS (178)
Alzheimer's disease (1729)
Antibody-drug conjugate (ADC) (330)
Approvals (16931)
Artificial intelligence (547)
Autoimmune disease (159)
Automation (39)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (653)
Cancer (4945)
Cardiovascular disease (418)
Career advice (1724)
Career pathing (38)
CAR-T (294)
CDC (46)
Celiac Disease (2)
Cell therapy (784)
Cervical cancer (36)
Clinical research (71457)
Collaboration (1805)
Company closure (4)
Compensation (1179)
Complete response letters (64)
COVID-19 (2771)
CRISPR (98)
C-suite (885)
Cystic fibrosis (152)
Data (6324)
Decentralized trials (2)
Denatured (39)
Depression (142)
Diabetes (505)
Diagnostics (6751)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (270)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (245)
Earnings (91456)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121023)
Executive appointments (1007)
FDA (19850)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1537)
Gene editing (214)
Generative AI (45)
Gene therapy (649)
GLP-1 (1011)
Government (4760)
Grass and pollen (6)
Guidances (384)
Healthcare (19206)
HIV (60)
Huntington's disease (46)
IgA nephropathy (87)
Immunology and inflammation (275)
Immuno-oncology (62)
Indications (111)
Infectious disease (3046)
Inflammatory bowel disease (198)
Inflation Reduction Act (17)
Influenza (119)
Intellectual property (253)
Interviews (315)
IPO (16932)
IRA (53)
Job creations (3713)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (85)
Layoffs (581)
Leadership (33)
Legal (8026)
Liver cancer (93)
Longevity (14)
Lung cancer (666)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (813)
MASH (171)
Medical device (13922)
Medtech (13975)
Mergers & acquisitions (20299)
Metabolic disorders (1322)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (340)
Neuropsychiatric disorders (97)
Neuroscience (3021)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4586)
Now hiring (67)
Obesity (633)
Opinion (282)
Ovarian cancer (168)
Pain (205)
Pancreatic cancer (233)
Parkinson's disease (294)
Partnered (34)
Patents (500)
Patient recruitment (504)
Peanut (57)
People (60323)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22474)
Phase 2 (31505)
Phase 3 (23291)
Pipeline (5349)
Policy (297)
Postmarket research (2602)
Preclinical (9606)
Press Release (67)
Prostate cancer (246)
Psychedelics (56)
Radiopharmaceuticals (298)
Rare diseases (895)
Real estate (6064)
Recruiting (71)
Regulatory (25011)
Reports (52)
Research institute (2486)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (77)
Schizophrenia (156)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (104)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3805)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (82)
Vaccines (1034)
Venture capital (95)
Weight loss (410)
Women's health (93)
Worklife (19)
Date
Today (45)
Last 7 days (626)
Last 30 days (2183)
Last 365 days (30782)
2026 (3533)
2025 (31063)
2024 (36298)
2023 (41016)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47417)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40708)
Australia (6763)
California (11509)
Canada (3312)
China (1143)
Colorado (487)
Connecticut (496)
Delaware (339)
Europe (89229)
Florida (1699)
Georgia (359)
Hawaii (3)
Idaho (61)
Illinois (885)
India (66)
Indiana (525)
Iowa (24)
Japan (438)
Kansas (130)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1407)
Massachusetts (8367)
Michigan (327)
Minnesota (641)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3063)
New Mexico (31)
New York (3013)
North Carolina (1535)
North Dakota (9)
Northern California (5600)
Ohio (338)
Oklahoma (21)
Oregon (45)
Pennsylvania (2304)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4463)
Tennessee (175)
Texas (1770)
United States (40932)
Utah (340)
Vermont (1)
Virginia (268)
Washington D.C. (82)
Washington State (956)
West Virginia (4)
Wisconsin (114)
Wyoming (2)
738,315 Results for "halozyme therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together
Both Halozyme and Elektrofi have partnered with several Big Pharma companies to provide drug delivery technologies.
October 2, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
January 5, 2026
·
6 min read
Patents
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme:
WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
March 5, 2025
·
1 min read
·
Dan Samorodnitsky
Biotech Beach
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme’s ENHANZE® manufacturing methods that the Company provides to its current and future licensees.
June 5, 2024
·
5 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Business
Halozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.
April 23, 2024
·
2 min read
Biotech Beach
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare conference.
June 4, 2024
·
2 min read
Business
Mahesh Krishnan Elected to Halozyme’s Board of Directors
Halozyme Therapeutics, Inc. announced the election of Mahesh Krishnan, M.D. to its Board of Directors.
April 25, 2024
·
4 min read
Business
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook.
May 7, 2024
·
17 min read
1 of 73,832
Next
